AbbVie Signs an Exclusive Worldwide License Option Agreement with Cugene for CUG252 to Treat Autoimmune Diseases
Shots:
- Cugene to receive $48.5M up front & will be eligible to receive development, regulatory, commercialization, sales-based milestones, and additional fees upon licensing option along with royalties
- AbbVie to acquire an exclusive option to license CUG252 & will lead the clinical development, manufacturing & commercialization activities for CUG252 if the option is exercised
- Cugene's CUG252 is an engineered IL-2 mutein that is used to treat autoimmune illnesses by selectively activating & expanding immune-suppressive Treg cells while lowering unwanted IL-2 activity on other IL-2 receptor-expressing cells. The therapy is being studied in a P-I study in healthy volunteers for the same indication
Ref: Abbvie | Image: Abbvie
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
